SYNTERA BIORISK
SpeciesCattleReleaseNetherlands · 2026-09-07
  1. Global Overview
  2. Europe
  3. Netherlands
  4. Lumpy skin disease
Country–disease dossierNetherlands · Lumpy skin disease
View economic evidence Run scenarioCompare interventionsInspect BCR assumptions Vaccine & intervention marketTrade analysis
Netherlands cross-disease portfolio NETHERLANDS DISEASE PROFILE · LINKED WORKSPACE

Lumpy skin disease

Official evidence, 12-province exposure and transparent national planning economics.

Profile readyEvidence + editable CBA
African swine fevernot present external incursion riskHighly pathogenic avian influenzacurrent 2026 infected holdingsBluetonguerecent epidemic no new 2025 detectionsBovine tuberculosisofficially free with residual import riskFoot-and-mouth diseaseofficially free without vaccinationPeste des petits ruminantsofficially freeNewcastle diseasecompulsory preventive vaccinationClassical swine feverofficially freeSheep pox and goat poxno current domestic event external incursion preparednessLumpy skin diseasefree status under external incursion pressureBovine viral diarrhoeaendemic control transitionJohne’s diseaseendemic quality assurance programmeEpizootic haemorrhagic diseasenotifiable no current domestic event in registered source
Official disease status · 2026-08-17

Lumpy skin disease

The Netherlands remains described as LSD-free, while outbreaks in France and Italy create a material introduction risk requiring tighter transport hygiene.

Selected geography
Netherlands
Susceptible livestock
3.64m
Evidence nature
Observed / official
Exposure layer

Netherlands · susceptible livestock

PDOK BRK 2026
Exposure is livestock inventory—not inferred prevalence. Regional selection updates supported evidence; the CBA remains explicitly national because regional cost evidence is unavailable.
Validated exposure

Netherlands

cattle3.64m

CBS 80783ENG · 2025 final observations; source grain retained.

Official signal at selected grain

No numeric national event series is published in the registered official source. The status narrative remains available.

Observed economics · national/source scope
Observed direct loss · national
N/A
Published programme cost · source scope
N/A
Monetised trade effect
N/A

No compatible current Netherlands-specific direct-loss estimate is registered; no value is inferred.

Relevant wildlife & interface

Wildlife evidence

No compatible current national wildlife-population layer is registered.

Population denominators remain unavailable unless explicitly registered; qualitative host evidence is not converted into a count.
ILLUSTRATIVE

Illustrative scenario—country-specific intervention evidence unavailable.

The planning parameters are retained, but the BCR is not estimated in this public profile.

Open Impact CalculatorWhy these assumptions?
Control choices

Default option scenarios

  1. 01Transport hygienePlanning option retained for explicit activation in Scenario Lab
  2. 02Vector controlPlanning option retained for explicit activation in Scenario Lab
  3. 03Emergency vaccination readinessPlanning option retained for explicit activation in Scenario Lab
Trade & movement

Documented consequence

Cattle transport from affected countries is subject to enhanced cleaning and disinfection; the national LSD playbook supports emergency response.

Registered sources document controls but not a compatible Netherlands-wide monetised consequence.
Evidence register

5 sources used in this view

Release principle: every Netherlands disease has a complete decision workspace. Missing observed economics stay visible as N/A; modelled planning values are separately labelled, editable and never presented as evidence.
Sustainability & One HealthCountry-specific GHG, AMU/AMR and biodiversity results remain withheld until compatible evidence is registered; none is inferred from the disease profile.
Request complete Decision Brief